全球高磷血症治疗市场：按产品类型、分销渠道、地区 - 预测和分析 (2022-2028)

全球高磷血症治疗市场规模预计将从 2021 年的 24.6 亿美元达到 2028 年的 35.3 亿美元，2022 年至 2028 年预测期内的复合年增长率预计为 5.3%。终末期肾病发病率的增加以及通过包括治疗在内的多学科方法对其进行管理的需求不断增长，正在推动市场增长。

本报告分析了全球高磷血症药物市场，并提供了系统的信息，包括市场概况、市场规模、市场动态和公司概况。

目录

执行摘要

市场概况

• 资料来源：执行摘要 - 市场概览图
• 资料来源：执行摘要 - 市场摘要数据表
• 资料来源：执行摘要——全球高磷血症市场特征说明
• 资料来源：执行摘要 - 市场区域：按地区
• 资源：执行摘要——市场细分图
• 资源：执行摘要 - 增量增长图
• 资料来源：执行摘要 - 增量增长数据表
• 资源：执行摘要 - 供应商市场定位图

母市场分析

市场概况

市场规模

• 市场动态
  • 资料来源：DROC 影响分析 (2021)
• 促进者
• 机会
• 抑製剂
• 任务
• SWOT分析

主要市场洞察

• 技术分析
  • （来源：数据表：技术名称及详情）
• 价格分析
  • （来源：数据表：技术名称及价格明细）
• 供应链分析
  • （来源：详细的供应链介绍）
• 价值链分析
  • （来源：详细的价值链介绍）
• 市场生态系统
  • 资料来源：母市场生态系统市场分析
  • 图：母市场的市场特征
• 知识产权分析
  • （来源：数据表：产品/技术名称、专利申请、发明人/公司名称、收购公司）
• 贸易分析
  • （来源：数据表：进出口数据明细）
• 启动分析
  • （来源：数据表：新兴创业公司详情）
• 原料分析
  • （来源：数据表：主要原材料图谱）
• 创新矩阵
  • （来源：定位矩阵：映射新技术和现有技术）
• 管道产品分析
  • （来源：数据表：公司名称和管道产品，按地区映射）
• 宏观经济指标

COVID-19 的影响

• 介绍
• 对经济情景评估的影响
  • 资料来源：GDP数据-同比增长（%）（2016-2022）
• 修正后的市场规模
  • 资料来源：全球高磷血症药物市场规模及预测数据表（百万美元）（2022-2028）
• COVID 对关键细分市场的影响
  • 资料来源：细分市场规模和预测数据表（百万美元）（2022-2028）
• COVID 策略：按公司分类
  • 资料来源：企业采用的主要战略分析

市场动态和前景

• 市场动态
  • 资料来源：DROC 影响分析 (2021)
• 促进者
• 机会
• 抑製剂
• 任务
• 监管状况
  • 资料来源：各地区法规数据表
• SWOT分析
• 波特分析
  • 竞争对手之间的竞争
• 图：竞争对手之间的敌对关係，主要因素的影响（2021）
  • 替代品的威胁
• 图表：替代产品威胁和关键因素的影响（2021 年）
  • 买方议价能力
• 图表：影响买家议价能力的关键因素（2021 年）
  • 新进入者的威胁
• 图表：新进入者威胁主要驱动因素的影响（2021 年）
  • 供应商的议价能力
• 图表：供应商议价能力威胁的主要驱动因素的影响（2021 年）
• Skyquest对未来混乱的特殊洞察
  • 政治影响
  • 经济影响
  • 社会影响
  • 技术影响
  • 对环境造成的影响
  • 法律影响
• 全球高磷血症药物市场，按产品类型
• 市场细分
• 资料来源：市场份额图表 (%) (2022-2028)
• 资料来源：市场份额数据表（%）（2022-2028）
• 司维拉姆
  • 市场估计和预测（2022-2028）
• 资料来源：市场份额图表 (%) (2022-2028)
• 资料来源：市场规模和预测（百万美元）（2022-2028）
• 钙基磷盲剂
  • 市场估计和预测（2022-2028）
• 资料来源：市场份额图表 (%) (2022-2028)
• 资料来源：市场规模和预测（百万美元）（2022-2028）
• 铁基磷结合剂
  • 市场估计和预测（2022-2028）
• 资料来源：市场份额图表 (%) (2022-2028)
• 资料来源：市场规模和预测（百万美元）（2022-2028）
• 碳酸镧
  • 市场估计和预测（2022-2028）
• 资料来源：市场份额图表 (%) (2022-2028)
• 资料来源：市场规模和预测（百万美元）（2022-2028）
• 非磷酸盐结合剂
  • 市场估计和预测（2022-2028）
• 资料来源：市场份额图表 (%) (2022-2028)
• 资料来源：市场规模和预测（百万美元）（2022-2028）
• 其他
  • 市场估计和预测（2022-2028）
• 资料来源：市场份额图表 (%) (2022-2028)
• 资料来源：市场规模和预测（百万美元）（2022-2028）
• 全球高磷血症药物市场：按分销渠道分类
• 市场细分
• 资料来源：市场份额图表 (%) (2022-2028)
• 资料来源：市场份额数据表（%）（2022-2028）
• 医院药房
  • 市场估计和预测（2022-2028）
• 资料来源：市场份额图表 (%) (2022-2028)
• 资料来源：市场规模和预测（百万美元）（2022-2028）
• 零售药店
  • 市场估计和预测（2022-2028）
• 资料来源：市场份额图表 (%) (2022-2028)
• 资料来源：市场规模和预测（百万美元）（2022-2028）
• 网上药店
  • 市场估计和预测（2022-2028）
• 资料来源：市场份额图表 (%) (2022-2028)
• 资料来源：市场规模和预测（百万美元）（2022-2028）

市场规模：按地区

• 北美
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他南美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲

主要公司简介

• 竞争格局
• 附件：受访企业（2021年）
• 附件：企业定位矩阵（2021）
• 附：公司市场份额饼图分析（%）（2021年）

Global Hyperphosphatemia Therapeutics Market was valued at USD 2.46 billion in 2021,and it is expected to reach USD 3.53 billion by 2028 at a CAGR of 5.3 % over the forecast period (2022-2028).

A condition called hyperphosphatemia is brought on by a high level of phosphate or phosphorous in the blood. The chemical phosphate, which contains the mineral phosphorous, is present in the body. The mineral phosphorus is crucial for the growth of teeth and bones as well as for converting food into body energy. The main locations of phosphate in the body are the teeth, bones, cells, and in very small quantities, the blood. The kidneys have a role in controlling the body's phosphate levels. However, a variety of issues or illnesses cause kidney damage, which results in a persistently high level of phosphate in the blood. People with end-stage kidney disease are more likely to develop hyperphosphatemia, which is very common in people with chronic kidney disease.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hyperphosphatemia Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. 

Segments covered in this report:

Global Hyperphosphatemia Therapeutics Market is segmented by Product Type, Distribution Channel, and Region. Based on Product Type, the market is segmented into Sevelamer, Calcium-based Phosphate Blinders, Iron-based Phosphate Binders, Lanthanum Carbonate, Non-phosphate Binders, and Others. Based on Distribution channels, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

Driver

An important driver that is enhancing the prospects for new pharmaceutical interventions in the market for treating hyperphosphatemia is the increasing incidence of end-stage renal disease. The available management options suggest using an integrated strategy to lower high levels of calcium and phosphorus. The patient population's high risk of cardiovascular events has increased the need for a multidisciplinary approach to managing it, including treatment. The market for treating hyperphosphatemia appears to have an unmet need for products combining calcium acetate and magnesium. The new class of phosphate binders is of particular interest. Clinical trials that specifically focus on evaluating them for their effectiveness, tolerability, and safety in advanced chronic kidney disease are therefore urgently needed (CKD).

Restraint

One of the main factors limiting the market's growth is poor treatment compliance among dialysis patients as a result of their heavy pill load. For instance, a dialysis patient is typically expected to take 10 to 12 different types of medications, according to a National Center for Biotechnology Information (NCBI) article. Nearly 80% of patients take four or more pills daily from phosphate binders, which can have negative side effects like gastrointestinal intolerance. Therefore, it is anticipated that these factors will limit the uptake of phosphate binders among CKD patients, thereby limiting the market's expansion.

Market Trends

It is very difficult to achieve ideal phosphate control in CKD patients receiving dialysis. The ability to control phosphate levels in dialysis patients has not significantly improved despite the extraordinary advancements in dialysis techniques over the years. Phosphate binders also have a number of negative side effects. Researchers are therefore concentrating on the introduction of new hyperphosphatemia therapeutics and updating the treatment guidelines in order to improve the treatment option for hyperphosphatemia. Phosphate binders are expected to be replaced by non-phosphate binders in the treatment of hyperphosphatemia, such as Tenapanor, an inhibitor of the hydrogen/sodium exchanger isoform 3 (NHE3), which is currently being researched. By 2021, the drug is expected to go on sale.

Table of Contents

Executive Summary

Market overview

• Exhibit: Executive Summary - Chart on Market Overview
• Exhibit: Executive Summary - Data Table on Market Overview
• Exhibit: Executive Summary - Chart on Global Global Hyperphosphatemia Therapeutics Market Characteristics
• Exhibit: Executive Summary - Chart on Market by Geography
• Exhibit: Executive Summary - Chart on Market Segmentation
• Exhibit: Executive Summary - Chart on Incremental Growth
• Exhibit: Executive Summary - Data Table on Incremental Growth
• Exhibit: Executive Summary - Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

• Market Dynamics
  • Exhibit: Impact analysis of DROC, 2021
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
• SWOT Analysis

KEY MARKET INSIGHTS

• Technology Analysis
  • (Exhibit: Data Table: Name of technology and details)
• Pricing Analysis
  • (Exhibit: Data Table: Name of technology and pricing details)
• Supply Chain Analysis
  • (Exhibit: Detailed Supply Chain Presentation)
• Value Chain Analysis
  • (Exhibit: Detailed Value Chain Presentation)
• Ecosystem Of the Market
  • Exhibit: Parent Market Ecosystem Market Analysis
  • Exhibit: Market Characteristics of Parent Market
• IP Analysis
  • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
• Trade Analysis
  • (Exhibit: Data Table: Import and Export data details)
• Startup Analysis
  • (Exhibit: Data Table: Emerging startups details)
• Raw Material Analysis
  • (Exhibit: Data Table: Mapping of key raw materials)
• Innovation Matrix
  • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
• Pipeline product Analysis
  • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
• Macroeconomic Indicators

COVID IMPACT

• Introduction
• Impact On Economy-scenario Assessment
  • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
• Revised Market Size
  • Exhibit: Data Table on Global Global Hyperphosphatemia Therapeutics Market size and forecast 2021-2027 ($ million)
• Impact Of COVID On Key Segments
  • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
• COVID Strategies By Company
  • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

• Market Dynamics
  • Exhibit: Impact analysis of DROC, 2021
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
• Regulatory Landscape
  • Exhibit: Data Table on regulation from different region
• SWOT Analysis
• Porters Analysis
  • Competitive rivalry
    • Exhibit: Competitive rivalry Impact of key factors, 2021
  • Threat of substitute products
    • Exhibit: Threat of Substitute Products Impact of key factors, 2021
  • Bargaining power of buyers
    • Exhibit: buyers bargaining power Impact of key factors, 2021
  • Threat of new entrants
    • Exhibit: Threat of new entrants Impact of key factors, 2021
  • Bargaining power of suppliers
    • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
• Skyquest special insights on future disruptions
  • Political Impact
  • Economic impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Global Hyperphosphatemia Therapeutics Market by Product Type

• Market segments
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Data table on Market share 2021-2027 (%)
• Sevelamer
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Calcium-based Phosphate Blinders
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Iron-based Phosphate Binders
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Lanthanum Carbonate
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Non-phosphate Binders
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Others
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)

Global Global Hyperphosphatemia Therapeutics Market by Distribution Channel

• Market segments
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Data table on Market share 2021-2027 (%)
• Hospital Pharmacies
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Retail Pharmacies
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Online Pharmacies
  • Market Estimates & Forecast, 2020-2027
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)

Market Size by Region

• Chart on Market share by geography 2021-2027 (%)
• Data Table on Market share by geography 2021-2027(%)
• North America
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • USA
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Canada
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Europe
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • Germany
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Spain
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • France
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • UK
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of Europe
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Asia Pacific
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • China
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • India
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Japan
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • South Korea
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of Asia Pacific
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Latin America
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • Brazil
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of South America
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
• Middle East & Africa (MEA)
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • GCC Countries
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • South Africa
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of MEA
    • Exhibit: Chart on Market share 2021-2027 (%)
    • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

• Competitive Landscape
  • Total number of companies covered
    • Exhibit: companies covered in the report, 2021
  • Top companies market positioning
    • Exhibit: company positioning matrix, 2021
  • Top companies market Share
    • Exhibit: Pie chart analysis on company market share, 2021(%)